Alopecia mucinosa and hypopituitarism.

Acta Derm Venereol

Published: March 1967

Download full-text PDF

Source

Publication Analysis

Top Keywords

alopecia mucinosa
4
mucinosa hypopituitarism
4
alopecia
1
hypopituitarism
1

Similar Publications

Folliculotropic mycosis fungoides (F-MF) is considered a unique variant of mycosis fungoides (MF), which is a form of cutaneous T-cell lymphomas (CTCLs). F-MF can appear in various forms, including patches, papules, plaques, nodules, and tumors. It often affects the face and extremities, with some cases involving the eyebrows.

View Article and Find Full Text PDF

Background: Folliculotropic mycosis fungoides (FMF) is a rare cutaneous malignancy that can be mistaken for inflammatory diseases, such as discoid lupus erythematosus (DLE), due to the variability of histopathological findings.

Methods: This study aims to provide dermatopathologists with evidence-based histopathologic criteria to distinguish DLE from FMF by reporting overlapping and distinguishing microscopic features. Forty-three biopsies from patients with a confirmed diagnosis of DLE or FMF were graded for the presence or absence of 18 histopathologic features.

View Article and Find Full Text PDF
Article Synopsis
  • Follicular Mycosis Fungoides (F-MF) is a rare variant of Mycosis Fungoides (MF), which is a type of skin lymphoma and should be considered when diagnosing hair loss.
  • Accurate diagnosis of F-MF relies on a detailed medical history, physical exams, and a combination of immunohistological and molecular analyses.
  • A case study of a 52-year-old man with recurrent scalp lesions demonstrated typical symptoms and histological features that led to a diagnosis of F-MF, highlighting the complexity of identifying this condition.
View Article and Find Full Text PDF
Article Synopsis
  • The case study investigates the effectiveness and safety of a Janus kinase (JAK) inhibitor for treating generalized eosinophilic pustular folliculitis (EPF) in a 16-year-old patient who did not respond to traditional treatments.
  • The patient was initially treated with oral tofacitinib, resulting in significant symptom relief, but a relapse occurred when the dosage was reduced.
  • A switch to the more selective JAK1 inhibitor upadacitinib led to complete recovery, suggesting that JAK inhibitors could be a viable option for EPF patients resistant to standard therapies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!